bioAffinity Technologies (BIAF) Liabilities and Shareholders Equity (2022 - 2025)
bioAffinity Technologies (BIAF) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $11.5 million as the latest value for Q3 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 76.23% to $11.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.4 million, a 3.8% decrease, with the full-year FY2024 number at $6.5 million, down 20.77% from a year prior.
- Liabilities and Shareholders Equity was $11.5 million for Q3 2025 at bioAffinity Technologies, up from $4.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.1 million in Q3 2022 to a low of $4.8 million in Q2 2025.
- A 4-year average of $8.7 million and a median of $8.2 million in 2023 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: plummeted 35.7% in 2024, then skyrocketed 76.23% in 2025.
- bioAffinity Technologies' Liabilities and Shareholders Equity stood at $12.2 million in 2022, then plummeted by 32.51% to $8.2 million in 2023, then decreased by 20.77% to $6.5 million in 2024, then skyrocketed by 77.26% to $11.5 million in 2025.
- Per Business Quant, the three most recent readings for BIAF's Liabilities and Shareholders Equity are $11.5 million (Q3 2025), $4.8 million (Q2 2025), and $5.5 million (Q1 2025).